Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26423374 | 0.94 | EGFR (0.38) | EGFRPIK3CDPIK3CAIMPDH2TDO2 | |
| SCHEMBL26423432 | 0.83 | EGFR (0.39) | EGFRPIK3CDPIK3CAIMPDH2TDO2 | |
| SCHEMBL26423276 | 0.83 | PDGFRB (0.45) | GRM4LMNANPC1HSP90AA1L3MBTL1 | |
| SCHEMBL26423356 | 0.83 | PDGFRB (0.40) | EGFRGRM4LMNANPC1HSP90AA1 | |
| SCHEMBL19758249 | 0.81 | AHR (0.45) | EGFRPIK3CDPIK3CAIMPDH2TDO2 | |
| SCHEMBL26423404 | 0.80 | ALDH1A1 (0.41) | EGFRPIK3CDPIK3CAIMPDH2TDO2 | |
| SCHEMBL26423400 | 0.79 | EGFR (0.36) | EGFRPIK3CDPIK3CAIMPDH2 | |
| SCHEMBL26423280 | 0.79 | CLK1 (0.39) | IMPDH2GRM4MAPK14NPC1KDM4E | |
| SCHEMBL26423455 | 0.77 | EGFR (0.39) | EGFRPIK3CDPIK3CAIMPDH2TDO2 | |
| SCHEMBL26423381 | 0.77 | MEN1 (0.39) | GRM4MAPK14LMNANPC1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127291-A1 | HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127291-A1 | HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL | OCIAD2, OCIAD1, AZI2 | EGFR 1270/4885PIK3CD 2623/4885PIK3CA 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.